As a Free StocksGuide user, you can view scores for all 7,021 stocks worldwide.
10 Analysts have issued a IN8bio Inc forecast:
10 Analysts have issued a IN8bio Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -22 -22 |
27%
27%
|
|
| EBIT (Operating Income) EBIT | -24 -24 |
25%
25%
|
|
| Net Profit | -24 -24 |
25%
25%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
| Head office | United States |
| CEO | William Ho |
| Employees | 18 |
| Founded | 2016 |
| Website | www.in8bio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


